Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Åkerblom L[au]:

Do biological medicinal products pose a risk to the environment?: a current view on ecopharmacovigilance. Kühler TC et al. Drug Saf. (2009)

Challenges with advanced therapy medicinal products and how to meet them. Committee for Advanced Therapies (CAT). et al. Nat Rev Drug Discov. (2010)

Vaccine protection against HIV-2 infection in cynomolgus monkeys. Putkonen P et al. AIDS Res Hum Retroviruses. (1991)

Search results

Items: 1 to 50 of 51

1.

Improvement and development of rapid chromatographic strip-tests for the diagnosis of rinderpest and peste des petits ruminants viruses.

Brüning-Richardson A, Akerblom L, Klingeborn B, Anderson J.

J Virol Methods. 2011 Jun;174(1-2):42-6. doi: 10.1016/j.jviromet.2011.03.016. Epub 2011 Mar 17.

PMID:
21419802
2.

Challenges with advanced therapy medicinal products and how to meet them.

Committee for Advanced Therapies (CAT); CAT Scientific Secretariat, Schneider CK, Salmikangas P, Jilma B, Flamion B, Todorova LR, Paphitou A, Haunerova I, Maimets T, Trouvin JH, Flory E, Tsiftsoglou A, Sarkadi B, Gudmundsson K, O'Donovan M, Migliaccio G, Ancāns J, Maciulaitis R, Robert JL, Samuel A, Ovelgönne JH, Hystad M, Fal AM, Lima BS, Moraru AS, Turcáni P, Zorec R, Ruiz S, Akerblom L, Narayanan G, Kent A, Bignami F, Dickson JG, Niederwieser D, Figuerola-Santos MA, Reischl IG, Beuneu C, Georgiev R, Vassiliou M, Pychova A, Clausen M, Methuen T, Lucas S, Schüssler-Lenz M, Kokkas V, Buzás Z, MacAleenan N, Galli MC, Linē A, Gulbinovic J, Berchem G, Fraczek M, Menezes-Ferreira M, Vilceanu N, Hrubisko M, Marinko P, Timón M, Cheng W, Crosbie GA, Meade N, di Paola ML, VandenDriessche T, Ljungman P, D'Apote L, Oliver-Diaz O, Büttel I, Celis P.

Nat Rev Drug Discov. 2010 Mar;9(3):195-201. doi: 10.1038/nrd3052. Review.

PMID:
20190786
3.

Do biological medicinal products pose a risk to the environment?: a current view on ecopharmacovigilance.

Kühler TC, Andersson M, Carlin G, Johnsson A, Akerblom L.

Drug Saf. 2009;32(11):995-1000. doi: 10.2165/11316540-000000000-00000. Review.

PMID:
19810773
4.

Neutralization of primary HIV-1 SF13 can be detected in extended incubation phase assays with sera from monkeys immunized with recombinant HIV-1 SF2 gp120.

Davis D, Donners H, Willems B, Lövgren-Bengtsson K, Akerblom L, Vanham G, Barnett S, Morein B, Heeney JL, van der Groen G.

Vaccine. 2004 Jan 26;22(5-6):747-54.

PMID:
14741168
5.

Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques.

Nilsson C, Sutter G, Walther-Jallow L, ten Haaft P, Akerblom L, Heeney J, Erfle V, Böttiger P, Biberfeld G, Thorstensson R.

J Gen Virol. 2002 Apr;83(Pt 4):807-18.

PMID:
11907330
6.

Development of a rapid chromatographic strip test for the pen-side detection of foot-and-mouth disease virus antigen.

Reid SM, Ferris NP, Brüning A, Hutchings GH, Kowalska Z, Akerblom L.

J Virol Methods. 2001 Aug;96(2):189-202.

PMID:
11445149
7.

Monoclonal antibodies to native HIV type 1 reverse transcriptase and their interaction with enzymes from different subtypes.

Rytting AS, Akerblom L, Albert J, Unge T, Björling E, Al-Khalili L, Gronowitz JS, Källander CF.

AIDS Res Hum Retroviruses. 2000 Sep 1;16(13):1281-94.

PMID:
10957725
8.

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine.

Cafaro A, Caputo A, Fracasso C, Maggiorella MT, Goletti D, Baroncelli S, Pace M, Sernicola L, Koanga-Mogtomo ML, Betti M, Borsetti A, Belli R, Akerblom L, Corrias F, Buttò S, Heeney J, Verani P, Titti F, Ensoli B.

Nat Med. 1999 Jun;5(6):643-50.

PMID:
10371502
9.

Colorimetric capture assay for human-immunodeficiency-virus-I reverse transcriptase activity.

Rytting AS, Akerblom L, Gronowitz JS, Källander CF.

Biotechnol Appl Biochem. 1999 Jun;29 ( Pt 3):241-50.

PMID:
10334955
10.

HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates.

Heeney J, Akerblom L, Barnett S, Bogers W, Davis D, Fuller D, Koopman G, Lehner T, Mooij P, Morein B, de Giuli Morghen C, Rosenwirth B, Verschoor E, Wagner R, Wolf H.

Immunol Lett. 1999 Mar;66(1-3):189-95.

PMID:
10203054
11.

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.

Verschoor EJ, Mooij P, Oostermeijer H, van der Kolk M, ten Haaft P, Verstrepen B, Sun Y, Morein B, Akerblom L, Fuller DH, Barnett SW, Heeney JL.

J Virol. 1999 Apr;73(4):3292-300.

12.

A colorimetric reverse transcriptase assay optimized for Moloney murine leukemia virus, and its use for characterization of reverse transcriptases of unknown identity.

Malmsten A, Ekstrand DH, Akerblom L, Gronowitz JS, Källander CF, Bendinelli M, Matteucci D.

J Virol Methods. 1998 Nov;75(1):9-20.

PMID:
9820570
13.

The role of type-1 and type-2 T-helper immune responses in HIV-1 vaccine protection.

Heeney JL, van Gils ME, van der Meide P, de Giuli Morghen C, Ghioni C, Gimelli M, Raddelli A, Davis D, Akerblom L, Morein B.

J Med Primatol. 1998 Apr-Jun;27(2-3):50-8.

PMID:
9747943
14.

beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques.

Heeney JL, Teeuwsen VJ, van Gils M, Bogers WM, De Giuli Morghen C, Radaelli A, Barnett S, Morein B, Akerblom L, Wang Y, Lehner T, Davis D.

Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10803-8.

16.

An immunoaffinity-purified Trypanosoma cruzi antigen suppresses cellular proliferation through a TGF-beta-mediated mechanism.

Hansen DS, Villacres-Eriksson M, Akerblom L, Hellman U, Segura E, Carlomagno M, Morein B.

Scand J Immunol. 1998 May;47(5):509-16.

17.

Identification of two antigenically and genetically distinct lineages of H3N8 equine influenza virus in Sweden.

Oxburgh L, Akerblom L, Fridberger T, Klingeborn B, Linné T.

Epidemiol Infect. 1998 Feb;120(1):61-70.

18.

A recombinant prime, peptide boost vaccination strategy can focus the immune response on to more than one epitope even though these may not be immunodominant in the complex immunogen.

Davis D, Morein B, Akerblom L, Lövgren-Bengtsson K, van Gils ME, Bogers WM, Teeuwsen VJ, Heeney JL.

Vaccine. 1997 Oct;15(15):1661-9.

PMID:
9364697
19.

Presentation of a foreign peptide on the surface of tomato bushy stunt virus.

Joelson T, Akerblom L, Oxelfelt P, Strandberg B, Tomenius K, Morris TJ.

J Gen Virol. 1997 Jun;78 ( Pt 6):1213-7.

PMID:
9191910
20.

Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.

Bolmstedt A, Sjölander S, Hansen JE, Akerblom L, Hemming A, Hu SL, Morein B, Olofsson S.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jul;12(3):213-20.

PMID:
8673525
23.

Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis.

Golovliov I, Ericsson M, Akerblom L, Sandström G, Tärnvik A, Sjöstedt A.

Vaccine. 1995 Feb;13(3):261-7.

PMID:
7631511
24.

The HIV-1 V3 domain on field isolates: participation in generation of escape virus in vivo and accessibility to neutralizing antibodies.

Arendrup M, Akerblom L, Heegaard PM, Nielsen JO, Hansen JE.

Arch Virol. 1995;140(4):655-70.

PMID:
7794110
25.

Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines.

de Vries P, Heeney JL, Boes J, Dings ME, Hulskotte EG, Dubbes R, Koornstra W, ten Haaft P, Akerblom L, Eriksson S, et al.

Vaccine. 1994 Nov;12(15):1443-52.

PMID:
7887023
26.

Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine.

Putkonen P, Björling E, Akerblom L, Thorstensson R, Lövgren K, Benthin L, Chiodi F, Morein B, Biberfeld G, Norrby E, et al.

J Acquir Immune Defic Syndr. 1994 Jun;7(6):551-9.

PMID:
8176640
27.

Mechanisms behind the immune response induced by immunostimulating complexes.

Morein B, Villacrés Eriksson M, Akerblom L, Rönnberg B, Lövgren K, Sjölander A.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S109-14. Review. No abstract available.

PMID:
7865283
28.

Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4.

Gram GJ, Hemming A, Bolmstedt A, Jansson B, Olofsson S, Akerblom L, Nielsen JO, Hansen JE.

Arch Virol. 1994;139(3-4):253-61.

PMID:
7832633
29.

Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1.

Levi M, Rudén U, Birx D, Loomis L, Redfield R, Lövgren K, Akerblom L, Sandström E, Wahren B.

J Acquir Immune Defic Syndr. 1993 Aug;6(8):855-64.

PMID:
8315572
30.

Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.

Arendrup M, Sönnerborg A, Svennerholm B, Akerblom L, Nielsen C, Clausen H, Olofsson S, Nielsen JO, Hansen JE.

J Gen Virol. 1993 May;74 ( Pt 5):855-63.

PMID:
7684062
31.

HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.

Akerblom L, Nara P, Dunlop N, Putney S, Morein B.

Biotechnol Ther. 1993;4(3-4):145-61.

PMID:
8292967
32.

Carbohydrate determinant NeuAc-Gal beta (1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120.

Bolmstedt A, Olofsson S, Sjögren-Jansson E, Jeansson S, Sjöblom I, Akerblom L, Hansen JE, Hu SL.

J Gen Virol. 1992 Dec;73 ( Pt 12):3099-105.

PMID:
1281869
33.

Antigen-specific increases in the number of splenocytes expressing MHC class II molecules following restimulation with antigen in various physical forms.

Bergström-Mollaoglu M, Lövgren K, Akerblom L, Fossum C, Morein B.

Scand J Immunol. 1992 Oct;36(4):565-74.

PMID:
1411302
34.
35.

Identification of amino acids in the V3 region of gp120 critical for virus neutralization by human HIV-1-specific antibodies.

Broliden PA, Mäkitalo B, Akerblom L, Rosen J, Broliden K, Utter G, Jondal M, Norrby E, Wahren B.

Immunology. 1991 Aug;73(4):371-6.

36.

Detection of porcine MHC class II antigens in different immunoassays.

Magnusson U, Akerblom L, Fossum C.

Zentralbl Veterinarmed B. 1991 Jul;38(5):321-8.

PMID:
1927146
37.

Cross-neutralizing antibodies to HIV-1 in mice after immunization with gp160 iscoms. Dissection of the immune response.

Akerblom L, Nara P, Dunlop N, Morein B.

AIDS Res Hum Retroviruses. 1991 Jul;7(7):621-7.

PMID:
1768464
38.

Vaccine protection against HIV-2 infection in cynomolgus monkeys.

Putkonen P, Thorstensson R, Walther L, Albert J, Akerblom L, Granquist O, Wadell G, Norrby E, Biberfeld G.

AIDS Res Hum Retroviruses. 1991 Mar;7(3):271-7.

PMID:
2064826
39.

Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120.

Akerblom L, Hinkula J, Broliden PA, Mäkitalo B, Fridberger T, Rosen J, Villacres-Eriksson M, Morein B, Wahren B.

AIDS. 1990 Oct;4(10):953-60.

PMID:
1702001
40.

A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization.

Broliden PA, Ljunggren K, Hinkula J, Norrby E, Akerblom L, Wahren B.

J Virol. 1990 Feb;64(2):936-40.

42.

Characterization of immunostimulating complexes (ISCOMS) of HIV-1.

Höglund S, Akerblom L, Ozel M, Villacres M, Eriksson M, Gelderblom HR, Arthur L, Morein B.

Viral Immunol. 1990 Fall;3(3):195-206.

PMID:
2257052
43.

Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120).

Pyle SW, Morein B, Bess JW Jr, Akerblom L, Nara PL, Nigida SM Jr, Lerche NW, Robey WG, Fischinger PJ, Arthur LO.

Vaccine. 1989 Oct;7(5):465-73.

PMID:
2554608
44.

Formation and characterization of FeLV ISCOMs.

Akerblom L, Strömstedt K, Hoglund S, Osterhaus A, Morein B.

Vaccine. 1989 Apr;7(2):142-6.

PMID:
2750272
45.

Serological responses in cats vaccinated with FeLV ISCOM and an inactivated FeLV vaccine.

Osterhaus A, Weijer K, UytdeHaag F, Knell P, Jarrett O, Akerblom L, Morein B.

Vaccine. 1989 Apr;7(2):137-41.

PMID:
2750271
46.

Free gp70 from FeLV: enrichment from cell culture fluid by ferric oxide-agarose chromatography.

Zelikman I, Akerblom L, Hjertèn S, Morein B.

Biotechnol Appl Biochem. 1989 Apr;11(2):209-16.

PMID:
2541738
47.
48.

Azidocytidine is a specific inhibitor of deoxyribonucleotide synthesis in 3T6 cells.

Akerblom L, Reichard P.

J Biol Chem. 1985 Aug 5;260(16):9197-202.

49.

Effects of azidocytidine on DNA synthesis and deoxynucleotide pools of mouse fibroblast cell lines.

Akerblom L, Pontis E, Reichard P.

J Biol Chem. 1982 Jun 25;257(12):6776-82.

50.

Overproduction of the free radical of ribonucleotide reductase in hydroxyurea-resistant mouse fibroblast 3T6 cells.

Akerblom L, Ehrenberg A, Gräslund A, Lankinen H, Reichard P, Thelander L.

Proc Natl Acad Sci U S A. 1981 Apr;78(4):2159-63.

Supplemental Content

Loading ...
Support Center